0001209191-23-009237.txt : 20230214 0001209191-23-009237.hdr.sgml : 20230214 20230214171220 ACCESSION NUMBER: 0001209191-23-009237 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230210 FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tatsis Ourania CENTRAL INDEX KEY: 0001789815 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 23631506 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS, INC. STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-10 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001789815 Tatsis Ourania C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Chief Reg. & Quality Off. Common Stock 2023-02-10 4 F 0 1377 294.33 D 69035 D Common Stock 2023-02-13 4 F 0 2995 298.26 D 66040 D Common Stock 2023-02-13 4 S 0 2 295.84 D 66038 D Common Stock 2023-02-13 4 S 0 78 298.11 D 65960 D Common Stock 2023-02-13 4 S 0 120 298.98 D 65840 D Common Stock 2023-02-13 4 S 0 64 299.88 D 65776 D Common Stock 2023-02-13 4 S 0 11 300.79 D 65765 D Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $298.11 (range $297.51 to $298.50). Open market sales reported on this line occurred at a weighted average price of $298.98 (range $298.53 to $299.50). Open market sales reported on this line occurred at a weighted average price of $299.88 (range $299.62 to $300.53). /s/ Christiana Stevenson, Attorney-in-Fact 2023-02-14